Univest
Univest
  • Markets

UTI Long Term Advantage Fund Series III vs SBI Series VI: NAV, Returns and Maturity Status Compared

  • July 21, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
UTI Long Term Advantage Fund Series III vs SBI Series VI

UTI Long Term Advantage Fund Series III NAV Rs 23.2926, 16.62% CAGR since 2016. SBI Long Term Advantage Fund NAV Rs 32.0297, 15.64% CAGR since 2018.

UTI Long Term Advantage Fund Series III vs SBI Series VI comes down to one key fact before any number matters: only one of these two schemes is still active today. The Fund B scheme in this comparison continues to publish a daily NAV of Rs 32.0297 per the latest AMFI data, while UTI Long Term Advantage Fund Series III matured in 2021 and paid out its investors at a final NAV of Rs 23.2926.

That difference shapes what UTI Long Term Advantage Fund Series III vs SBI Series VI means for you. If you hold units in either scheme, the lock in period has ended, so the choice is between redeeming now, holding until maturity, or reallocating toward an open ended ELSS fund that accepts fresh money and runs a SIP.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • UTI Long Term Advantage Fund Series III vs SBI Series VI: Quick Comparison Table
  • UTI Long Term Advantage Fund Series III vs SBI Series VI: NAV and Live Performance
  • UTI Long Term Advantage Fund Series III vs SBI Series VI: Maturity and Investment Status
  • UTI Long Term Advantage Fund Series III vs SBI Series VI: Which Fund Performed Better
  • UTI Long Term Advantage Fund Series III vs SBI Series VI: Key Takeaways for Tax Saving Investors
  • Conclusion
  • FAQs on UTI Long Term Advantage Fund Series III vs SBI Series VI
    • In UTI Long Term Advantage Fund Series III vs SBI Series VI, which fund performed better?
    • What is the latest NAV of UTI Long Term Advantage Fund Series III in UTI Long Term Advantage Fund Series III vs SBI Series VI?
    • Is the comparison fund in UTI Long Term Advantage Fund Series III vs SBI Series VI still active?
    • Can I invest in either fund from UTI Long Term Advantage Fund Series III vs SBI Series VI today?
    • What type of fund is UTI Long Term Advantage Fund Series III?
    • What returns has UTI Long Term Advantage Fund Series III delivered?
    • What happened to investors in the UTI Long Term Advantage Fund Series III vs SBI Series VI comparison at maturity?
    • What is the key takeaway from UTI Long Term Advantage Fund Series III vs SBI Series VI?

UTI Long Term Advantage Fund Series III vs SBI Series VI: Quick Comparison Table

The table below sets out UTI Long Term Advantage Fund Series III vs SBI Series VI on structure, NAV and verified returns computed from official AMFI NAV history.

Parameter UTI Long Term Advantage Fund Series III SBI Long Term Advantage Fund – Series VI
Fund house UTI Mutual Fund SBI Mutual Fund
Category Close ended ELSS Close ended ELSS
Units allotted 2016 2018
Current status Matured in 2021 Live, matures around 2028
Latest / final NAV Rs 23.2926 Rs 32.0297
CAGR since launch 16.62% per year 15.64% per year
Total return since launch About 132.4% About 219.2%
Lock in 3 years (already over) 3 years (already over)
Fresh investment allowed No, NFO only scheme No, NFO only scheme

UTI Long Term Advantage Fund Series III vs SBI Series VI: NAV and Live Performance

The UTI Long Term Advantage Fund Series III side of UTI Long Term Advantage Fund Series III vs SBI Series VI has compounded investor money at 16.62 percent per year since units were allotted in 2016, a total gain of about 132.4 percent to date. Based on AMFI NAV history, it has also delivered a 3 year CAGR of 18.67 percent and a 5 year CAGR of 15.21 percent.

The comparison fund in UTI Long Term Advantage Fund Series III vs SBI Series VI, SBI Long Term Advantage Fund – Series VI, has compounded at 15.64 percent per year since 2018, a total return of about 219.2 percent and is still adding to that figure today.

Use the Univest Screener to Compare Live Fund and Stock Data

UTI Long Term Advantage Fund Series III vs SBI Series VI: Maturity and Investment Status

Structurally, UTI Long Term Advantage Fund Series III is a close ended ELSS. It accepted money only during its 2016 new fund offer, gave investors Section 80C tax benefits, and imposed a three year lock in. Since that lock in ended, unitholders have been free to redeem on any business day at NAV, and the scheme has since completed its full life cycle and matured.

The comparison fund in UTI Long Term Advantage Fund Series III vs SBI Series VI followed the same structure. It remains live and unitholders can redeem freely at the current NAV of Rs 32.0297 at any time before its eventual maturity.

UTI Long Term Advantage Fund Series III vs SBI Series VI: Which Fund Performed Better

On pure lifetime CAGR, UTI Long Term Advantage Fund Series III vs SBI Series VI tilts toward UTI Long Term Advantage Fund Series III, which has compounded at 16.62 percent per year versus 15.64 percent per year for the other scheme. Entry and exit timing plays a real role here since ELSS NFOs launched in different market cycles naturally show different lifetime returns.

Total wealth created can tell a different story than annualised CAGR in UTI Long Term Advantage Fund Series III vs SBI Series VI. A scheme that has stayed invested longer compounds a larger absolute gain even at a lower annual rate, while a matured scheme locks in its return the moment it closes and forces the investor to find a new home for that money, which carries its own reinvestment risk.

The honest verdict from UTI Long Term Advantage Fund Series III vs SBI Series VI is that both schemes broadly did their job as Section 80C tax savers. Each one delivered a healthy multi year return well ahead of inflation. The bigger lesson from UTI Long Term Advantage Fund Series III vs SBI Series VI sits in the close ended structure itself, not in which fund edged ahead.

UTI Long Term Advantage Fund Series III vs SBI Series VI: Key Takeaways for Tax Saving Investors

Close ended ELSS schemes, as UTI Long Term Advantage Fund Series III vs SBI Series VI shows, are largely a discontinued category today. You cannot add money after the NFO, you cannot run a SIP, and your exit at maturity may or may not land in a favourable market. Open ended ELSS funds solve all three problems while offering the same Section 80C benefit and the same three year lock in per instalment.

If you still hold either fund from UTI Long Term Advantage Fund Series III vs SBI Series VI, review it the way you would any equity fund. The lock in is over on both sides, so the choice between redeeming now and holding until maturity should rest on your goals, your tax situation on gains, and whether the money has a better destination. A SEBI registered investment adviser can help you weigh that call against your full portfolio.

Many investors researching UTI Long Term Advantage Fund Series III vs SBI Series VI also want to know how the lock in and tax treatment compare before deciding where to hold their money.

For a reader evaluating UTI Long Term Advantage Fund Series III vs SBI Series VI, the NAV figures above are the fastest way to see which scheme has compounded faster to date.

UTI Long Term Advantage Fund Series III vs SBI Series VI is a useful reference point whenever either scheme comes up in a broader ELSS portfolio review.

Anyone tracking UTI Long Term Advantage Fund Series III vs SBI Series VI should note that neither scheme is open for new lump sum or SIP investment today.

The comparison in UTI Long Term Advantage Fund Series III vs SBI Series VI is most useful for existing unitholders deciding whether to redeem, hold, or reinvest elsewhere.

Download the Univest iOS App or Univest Android App to track funds, stocks and SEBI registered research in one place.

Conclusion

UTI Long Term Advantage Fund Series III vs SBI Series VI ultimately does not favour one fund by a wide margin. UTI Long Term Advantage Fund Series III shows a verified CAGR of 16.62 percent since 2016, while the comparison fund has compounded at 15.64 percent since 2018. Neither side of UTI Long Term Advantage Fund Series III vs SBI Series VI accepts fresh money today, so for new tax saving investment in FY 2026-27, an open ended ELSS with a consistent track record is the practical route. Historically, disciplined ELSS investing has rewarded patience, but always consult a SEBI registered adviser before acting.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs on UTI Long Term Advantage Fund Series III vs SBI Series VI

In UTI Long Term Advantage Fund Series III vs SBI Series VI, which fund performed better?

Ans. On lifetime CAGR, UTI Long Term Advantage Fund Series III finished ahead at about 16.62 percent per year, versus 15.64 percent per year for the other scheme in this comparison. Total wealth created can still favour the scheme that has stayed invested longer, even at a lower annual rate.

What is the latest NAV of UTI Long Term Advantage Fund Series III in UTI Long Term Advantage Fund Series III vs SBI Series VI?

Ans. The final NAV of UTI Long Term Advantage Fund Series III is Rs 23.2926, per official AMFI data, declared in 2021 at maturity.

Is the comparison fund in UTI Long Term Advantage Fund Series III vs SBI Series VI still active?

Ans. Yes, it continues to publish a daily NAV of Rs 32.0297 per the latest AMFI data and remains open for redemption at any time.

Can I invest in either fund from UTI Long Term Advantage Fund Series III vs SBI Series VI today?

Ans. No fresh investment is possible in either scheme covered in UTI Long Term Advantage Fund Series III vs SBI Series VI. Both are close ended ELSS schemes that accepted subscriptions only during their respective new fund offers, and neither is accepting or holding new investor money now.

What type of fund is UTI Long Term Advantage Fund Series III?

Ans. UTI Long Term Advantage Fund Series III is a close ended equity linked savings scheme, or ELSS, from UTI Mutual Fund. Investments made during its NFO qualified for Section 80C tax deduction and carried a three year lock in period.

What returns has UTI Long Term Advantage Fund Series III delivered?

Ans. UTI Long Term Advantage Fund Series III has compounded at roughly 16.62 percent per year since its 2016 launch, a total gain of about 132.4 percent, with a 3 year CAGR of 18.67 percent per the latest AMFI NAV history.

What happened to investors in the UTI Long Term Advantage Fund Series III vs SBI Series VI comparison at maturity?

Ans. At maturity, outstanding units were compulsorily redeemed at the prevailing NAV and the proceeds were paid to unitholders. This is the standard process for every close ended ELSS scheme once its tenure ends.

What is the key takeaway from UTI Long Term Advantage Fund Series III vs SBI Series VI?

Ans. The key takeaway from UTI Long Term Advantage Fund Series III vs SBI Series VI is that close ended ELSS schemes cannot take fresh money after their NFO, so investors comparing them today should treat this as a reference case rather than a live investment choice. An open ended ELSS fund with a consistent long term record is the practical route for new tax saving investment.



News
Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply